Everything below concerns PPARδ agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Many of the city's leading merchants were involved in smuggling at this time, illicitly exporting goods like foodstuffs and leather, while under-declaring imports of wine. In 1574 Elizabeth I visited the city during her Royal Progress through the western counties. The city burgesses spent over one thousand pounds on preparations and entertainments, most of which was raised by special rate assessments. In 1577 the explorer Martin Frobisher arrived in the city with two ships and samples of ore, which proved to be worthless. He also brought, according to Latimer "three savages, doubtless Esqiumaux, clothed in deerskins, but all of them died within a month of their arrival." Bristol sent three ships to the Royal Navy fleet against the Spanish Armada in 1588, and also supplied two levies of men to the defending land forces. Despite appeals to the Privy Council no reimbursement was made for these supplies. The corporation also had to repair the walls and gates of the city. The castle had fallen into disuse in the late Tudor era, but the City authorities had no control over royal property and the precincts became a refuge for lawbreakers. Anne of Denmark came to Bristol in June 1613 and was welcomed by the mayor Abel Kitchin. The visit featured a pageant on the river, with an English ship attacked by Turkish galleys, which the queen watched from the Canon's Marsh meadow near the cathedral. An English victory was signalled by the release of six bladders of pig's blood poured out of the ship's scupper holes.
doi:10.1086/590941. PMID 18665816. Wikidata Q45138244. Rajan P Adhikari; Cook, Gregory Murray; Lamont, Iain; Selwyn Lang; Heffernan, Helen Mary; John M B Smith (2002). "Phenotypic and molecular characterization of community occurring, Western Samoan phage pattern methicillin-resistant Staphylococcus aureus". Journal of Antimicrobial Chemotherapy. 50 (6): 825–831. doi:10.1093/jac/dkf242. PMID 12461000. Wikidata Q40686052.
=== 2000–2002: The beginning of the rivalry === 50 Cent's single "How to Rob" quickly became an underground hit throughout New York and 50 Cent soon began work on his major label debut Power of the Dollar, set for release in 2000. Despite 50 Cent's local success with "How To Rob", his local success paled in comparison to Ja Rule's following the release of Rule 3:36 later that same year. Tensions began to form beyond conflicts between the two crews and record labels. In February 2000, both 50 Cent and Ja Rule were scheduled to perform at the same Atlanta nightclub. Prior to the performances, music executive Chaz “Slim” Williams who was managing 50 Cent at the time, arranged a meeting between 50 Cent and Ja Rule to discuss ending their dispute. According to multiple accounts, the meeting escalated into a physical altercation after Ja Rule, who was holding a baseball bat, allegedly made threatening gestures toward 50 Cent. In response, 50 Cent reportedly attempted to strike Ja Rule, prompting a scuffle between the two. Accounts of the incident differ regarding what occurred next. 50 Cent has claimed to have punched Ja Rule, knocked him unconscious and took his chain while Ja Rule has maintained that he struck 50 Cent with the baseball bat before the two engaged in a physical struggle. Black Child, an associate of Ja Rule, later alleged that members of Ja Rule’s entourage chased 50 Cent through a nearby hotel following the incident.
Hyperforin is a phytochemical produced by some of the members of the plant genus Hypericum, notably Hypericum perforatum (St John's wort). Hyperforin may be involved in the pharmacological effects of St. John's wort, specifically in its antidepressant effects. Meta-analyses of clinical trials suggest that H. perforatum is as effective as SSRIs for treating mild to moderate depression and is better tolerated, although findings are limited by short study durations. Hyperforin is found in significant amounts only in H. perforatum, where it accumulates as a probable plant defense compound, with modern carbon dioxide extraction methods used to isolate it from mixtures containing related compounds like adhyperforin.
Sources: en.wikipedia.org
==== Front end ==== Waste from the front end of the nuclear fuel cycle is usually alpha-emitting waste from the extraction of uranium. It often contains radium and its decay products. Uranium dioxide (UO2) concentrate from mining is a thousand or so times as radioactive as the granite used in buildings. It is refined from yellowcake (U3O8), then converted to uranium hexafluoride gas (UF6). As a gas, it undergoes enrichment to increase the U-235 content from 0.7% to about 4.4% (LEU). It is then turned into a hard ceramic oxide (UO2) for assembly as reactor fuel elements. The main by-product of enrichment is depleted uranium (DU), principally the U-238 isotope, with a U-235 content of ~0.3%. It is stored, either as UF6 or as U3O8. Some is used in applications where its extremely high density makes it valuable such as anti-tank shells, and on at least one occasion even a sailboat keel. It is also used with plutonium for making mixed oxide fuel (MOX) and to dilute, or downblend, highly enriched uranium from weapons stockpiles which is now being redirected to become reactor fuel.
He had wanted to say: "You sound as though from the tomb", but instead he told Thomas that he sounded like Louis Armstrong. Later, Thomas went drinking with Reitell at the White Horse and, feeling sick again, returned to the hotel. Feltenstein came to see him three times that day, administering the cortisone secretant ACTH by injection (a tropic peptide hormone produced and secreted by the anterior pituitary gland) and, on his third visit, half a grain (32.4 milligrams) of morphine sulphate. This amount was three times more than was medically appropriate and was, by affecting Thomas's breathing and consequently the oxygen supply to his brain, the precipitating cause of the coma from which he would never awake. After Reitell became increasingly concerned and telephoned Feltenstein for advice he suggested she get male assistance, so she called upon the painter Jack Heliker, who arrived before 11 pm. At midnight on 5 November, Thomas's breathing became more difficult and his face turned blue. Reitell phoned Feltenstein who arrived at the hotel at about 1 am, and called for an ambulance. It then took another hour for the ambulance to arrive at St. Vincent's, even though it was only a few blocks from the Chelsea. Thomas was admitted to the emergency ward at St Vincent's Hospital at 1:58 am. He was comatose, and his medical notes state that "the impression upon admission was acute alcoholic encephalopathy damage to the brain by alcohol, for which the patient was treated without response".
=== Dance === Alongside her screen career, Kallingal has maintained an active presence as a performer and choreographer. In 2014 she established Mamangam, a dance studio in Kochi, which closed in 2021 due to the COVID-19 pandemic. She subsequently reconstituted it as Mamangam Dance Company, which continues to produce and tour contemporary dance work. In November 2023, Mamangam Dance Company presented its debut full-length contemporary dance production, Neythe — Dance of the Weaves, at the Fine Arts Society Hall, Kochi. The 35-minute work paid tribute to the handloom weavers of Chendamangalam and was inspired by the displacement of livelihoods after the 2018 Kerala floods. The production was staged at the International Theatre Festival of Kerala in Thrissur in March 2025. Kallingal also created Nayika, a one-hour dance production tracing a century of women in Malayalam cinema, beginning with a tribute to P. K. Rosy, the industry's first actress.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.